Table 1.
Clinical features of human endometrial cancer
| Total | Low-risk | High-risk | Recurrence | |
|---|---|---|---|---|
| n (%) |
34 (100) |
7 (21) |
27 (79) |
7 (21) |
| Age, mean (range) |
59 (38–78) |
58 (38–75) |
60 (45–78) |
56 (45–67) |
| FIGO stage, n (%) |
|
|
|
|
| I |
15 (44) |
7 (100) |
8 (30) |
1 (14) |
| II |
3 (9) |
0 (0) |
3 (11) |
1 (14) |
| III |
14 (41) |
0 (0) |
14 (52) |
3 (43) |
| IV |
2 (6) |
0 (0) |
2 (7) |
2 (29) |
| Grade, n (%) |
|
|
|
|
| 1 |
15 (44) |
5 (71) |
10 (37) |
0 (0) |
| 2 |
13 (38) |
2 (29) |
11 (41) |
6 (86) |
| 3 |
6 (18) |
0 (0) |
6 (22) |
1 (14) |
| Lymphovascular space invasion, n (%) |
|
|
|
|
| + |
10 (29) |
0 (0) |
10 (37) |
2 (29) |
| - |
24 (71) |
7 (100) |
17 (63) |
5 (71) |
| MIR31, mean |
18.40 |
2.05 |
21.90 |
9.15 |
| (range) | (0.15 - 284.06) | (0.33 - 5.98) | (0.15 - 284.06) | (0.70 - 27.77) |